Abstract:The nucleotide-binding, oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a multiprotein complex that combines sensing, regulation, and effector functions to regulate inflammation in health and disease. NLRP3 is activated by a diverse range of inflammation-instigating signals known as pathogen associated molecular patterns and danger associated molecular patterns. Upon activation, NLRP3 oligomerizes and recruits partner proteins to form a supramolecular platform to process the maturation and release of interleukin (IL)-1 β , IL-18, and gasdermin D, major mediators of inflammation and inflammatory cell death termed pyroptosis. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide range of disease conditions, including chronic inflammatory disease that are associated with lifestyle and dietary changes, aging, and environmental exposures, and have become the leading cause of death worldwide. Pharmacological targeting of NLRP3 and signaling demonstrated promising efficacy in ameliorating a list of disease conditions in animal models. These findings underscore the potential and importance of NLRP3 as a druggable target for treating a range of diseases. In this review, recent progress in understanding the structure and mechanism of action of the NLRP3 inflammasome is discussed with focus on pharmacological inhibition of NLRP3 by small molecule inhibitors. New structural and mechanistic insights into NLRP3 activation and inhibitor-NLRP3 interactions would aid in the rational design and pharmacological evaluation of NLRP3 inhibitors for treatment of human disease. Significance Statement The NLRP3 inflammasome plays central role in innate immune sensing and control of inflammation. Pharmacological inhibition of NLRP3 demonstrated promising efficacy in a range of diseases in animal models. Recent elucidation of the structure and inhibitor binding of NLRP3 generated new insights into its mode of action and inhibitor-NLRP3 interaction at molecular levels, providing new framework for developing small chemical inhibitors of NLRP3 with improved efficacy and specificity against chronic disease that has become major health concerns worldwide.

A Dynamic Protocol to Explore NLRP3 Inflammasome Activation in Cerebral Organoids

The NLRP3 Inflammasome is Involved in Resident Intruder Paradigm-Induced Aggressive Behaviors in Mice

Targeting NLRP3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders

NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies

NLRP3 monomer Functional Dynamics: from the Effects of Allosteric Binding to Implications for Drug Design

Spatiotemporal proteomic profiling of cellular responses to NLRP3 agonists

A microglia-containing cerebral organoid model to study early life immune challenges

Recent Advances of the NLRP3 Inflammasome in Central Nervous System Disorders.

Role of NLRP3 inflammasome in central nervous system diseases

Dynamic neuroinflammatory profiles predict Alzheimer’s disease pathology in microglia-containing cerebral organoids

Covalent Targeting As a Common Mechanism for Inhibiting NLRP3 Inflammasome Assembly

Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases

Preclinical translational platform of neuroinflammatory disease biology relevant to neurodegenerative disease

The Potential of NLRP3 Inflammasome As a Therapeutic Target in Neurological Diseases.

Recent Insights into the Regulatory Networks of NLRP3 Inflammasome Activation

Focus on the Role of NLRP3 Inflammasome in Diseases

Pharmacological Inhibitors of the NLRP3 Inflammasome

NLRP3 Inflammasome Activation: A Therapeutic Target for Cerebral Ischemia–Reperfusion Injury

Targeting NLRP3 inflammasome for neurodegenerative disorders

Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction

Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation